Short Interest in Cytosorbents Co. (NASDAQ:CTSO) Grows By 5.4%

Cytosorbents Co. (NASDAQ:CTSO) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,370,000 shares, a growth of 5.4% from the November 15th total of 1,300,000 shares. Based on an average trading volume of 123,700 shares, the short-interest ratio is presently 11.1 days.

Cytosorbents Price Performance

CTSO stock traded down $0.07 during midday trading on Tuesday, hitting $0.84. The company’s stock had a trading volume of 131,529 shares, compared to its average volume of 126,258. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average of $0.97 and a two-hundred day moving average of $1.02. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $2.15. The firm has a market capitalization of $45.93 million, a price-to-earnings ratio of -2.53 and a beta of 0.57.

Hedge Funds Weigh In On Cytosorbents

Hedge funds have recently bought and sold shares of the company. CM Management LLC grew its holdings in Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Atomi Financial Group Inc. acquired a new position in shares of Cytosorbents in the 3rd quarter worth $51,000. Finally, Sargent Investment Group LLC boosted its position in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on CTSO. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com began coverage on Cytosorbents in a research note on Thursday, December 12th. They issued a “hold” rating on the stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.